TSE - Trinseo S.A.

NYSE - NYSE Delayed Price. Currency in USD
-1.52 (-5.22%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close29.12
Bid27.54 x 900
Ask57.75 x 800
Day's Range27.36 - 28.95
52 Week Range27.36 - 82.18
Avg. Volume359,110
Market Cap1.127B
Beta (3Y Monthly)2.01
PE Ratio (TTM)5.70
EPS (TTM)4.84
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & Yield1.60 (4.38%)
Ex-Dividend Date2019-07-10
1y Target Est39.67
Trade prices are not sourced from all markets
  • Business Wire

    Trinseo Increases Prices for Latex Technologies in North America

    Trinseo a global materials company and manufacturer of plastics, latex and rubber, today announced that effective September 16, 2019, the company is increasing the prices of all Styrene Butadiene and Styrene Acrylate products sold into the carpet, paper, and paperboard markets in North America.

  • GuruFocus.com

    Trinseo Sa (TSE) President and CEO Frank A Bozich Bought $434,550 of Shares

    President and CEO of Trinseo Sa (30-Year Financial, Insider Trades) Frank A Bozich (insider trades) bought 15,000 shares of TSE on 08/14/2019 at an average price of $28.97 a share. Continue reading...

  • Philadelphia companies hit hard by sharp stock market declines
    American City Business Journals

    Philadelphia companies hit hard by sharp stock market declines

    Among the Philadelphia region’s largest 20 publicly traded companies, the biggest losers were two chemical companies.

  • Thomson Reuters StreetEvents

    Edited Transcript of TSE earnings conference call or presentation 9-Aug-19 2:00pm GMT

    Q2 2019 Trinseo SA Earnings Call

  • Trinseo (TSE) Earnings Lag Estimates in Q2, Revenues Down Y/Y

    Trinseo (TSE) Earnings Lag Estimates in Q2, Revenues Down Y/Y

    Trinseo (TSE) faced challenges from a difficult business environment in Q2. The company expects adjusted earnings of $4.15-$4.86 per share for 2019.

  • Is Trinseo S.A. (NYSE:TSE) Potentially Underrated?
    Simply Wall St.

    Is Trinseo S.A. (NYSE:TSE) Potentially Underrated?

    Trinseo S.A. (NYSE:TSE) is a company with exceptional fundamental characteristics. Upon building up an investment case...

  • RBC Capital: 3 Top Gold Stocks To Buy Now

    RBC Capital: 3 Top Gold Stocks To Buy Now

    Gold prices are soaring right now. Last week gold hit a six-year high and broke through the critical $1,500/oz level. This was on the back of multiple factors, including market concerns around low global growth rates and trade, lower real rates in the US (and globally), and a weaker US dollar. For instance, the 10-year US Treasury yield is now at just 1.7% from highs of +3.2% in Q4 last year. Let the good times roll for this classic safe-haven asset, says RBC Capital. The firm believes the industry is ‘now in a potential sweet spot’ and sees a number of compelling precious metal opportunities. “We think the coming 12 months could be a sweet spot for investors as higher prices boost margins and cash generation, but management teams don't have the mandate (yet) to pull the trigger on potentially value eroding "actions" such as new growth... This could lead to higher cashflow, rapid deleveraging and increased dividends,” says the firm. As a result, it believes street upgrades could roll through in the coming quarters. And in the meantime, RBC Capital has pinpointed a few top stocks for investors to consider. Indeed, as the firm writes: “Whilst a rising tide to some extent lifts all boats, we believe there will be relative winners.” Here are three names that stand out right now: Endeavour Mining (TSE:EDV)Endeavour Mining is a West African gold producer with a number of producing and near-producing mines. According to RBC Capital, Endeavour screens well on both strategy and deleveraging. “With a refreshed senior management team and board of directors, we believe Endeavour is well positioned to drive long-term value through a "back-to-basics" approach” says the firm.In its most recent report on the stock, analyst Wayne Lam reiterated a buy rating for EDV with a C$28 price target. This suggests significant upside potential of over 40%. “We expect the shares should benefit from a number of key catalysts over the coming months including the start-up of the Ity CIL project, inaugural reserve on the Kari Pump deposit at Hounde, and updated resource on the La Plaque deposit at Ity” the analyst told investors. He is forecasting annual production of 175 Koz at the Ity mine, on costs of $700/oz over a 19-year mine life.Encouragingly, all six analysts covering the stock rate EDV a buy right now. And the average price target suggests that shares can surge over 20% from current levels in the coming months. "We forecast... very strong positive FCF in Q4, when the Ity CIL project in Côte d’Ivoire will be fully ramped up to the expanded production rate" stated Berenberg's Michael Stoner on August 2.Following a very strong start for the Ity mine, Stoner (a 3-star analyst according to TipRanks) believes investors can look forward to "a sustained period of cash generation, de-gearing and the start of shareholder returns." AngloGold Ashanti Ltd (NYSE:AU)For global investors AngloGold looks like a catalyst rich story, cheers RBC Capital. This is the world’s third largest gold mining company (by production) with operations spanning Africa, the Americas, Australasia and South Africa.Late last month RBC Capital’s James Bell hosted investor meetings with the company’s relatively new CEO Kelvin Dushnisky. Priorities for the business remain 1) Streamlining the portfolio, 2) Obuasi start-up (first gold is expected in the fourth quarter of this year) and 3) Reducing net debt towards 1.0x EBITDA. Discussions also covered dividends and growth projects, reported Bell. Following the meetup, he reiterated his buy rating and price target indicating 17% upside potential from current levels. Bell believes that sales of both Cerro Vanguardia in Argentina and the remaining South Africa assets could be catalysts for the stock, “particularly as an exit from the SA operating could help remove a "layer" of the group's discount to global peers.”Like Bell, BMO Capital’s Andrew Kaip (a 3-star analyst) also recently upgraded AU from hold to buy. Kaip cited a more constructive gold outlook and confidence in the delivery of the Obuasi project, adding: “we are of the view that AngloGold is one of the better large gold producers for exposure to a rising gold price.” These are the only two analysts covering the stock right now- hence the stock’s Moderate Buy consensus. B2Gold (TSE:BTO) (NYSEMKT:BTG)Canadian gold producer B2Gold is the third gold stock boasting a bullish rating from RBC Capital. That’s thanks to the company’s impressively strong growth profile. It owns five producing mines (in the Philippines, Namibia, Mali and Nicaragua), two development projects and several exploration assets. BTO is buzzing right now after it reported stellar earning results for the second quarter. Results came in above consensus driven by higher production and lower costs at both Fekola and Masbate. “The ramp up of the mill expansion at Fekola appears to be ahead of schedule and full year guidance was reiterated with the strong operating result through H1/19” commented RBC Capital’s Stephen Walker (a 3-star analyst) post-beat. He expects investors to continue to focus on 1) the expansion at Fekola, 2) ongoing deleveraging of the balance sheet, and 3) exploration updates. Meanwhile top BMO Capital analyst Brian Quast (a 5-star analyst) marginally boosted his price target from $5.50 to $6, explainig “We have increased our P/NPV valuation multiple for B2Gold to 2.0x P/NPV from 1.5x to reflect the company's consistently strong execution and its divestiture of assets in politically riskier jurisdictions.” The analyst concludes: “We believe the company is a proven, competent operator with a well diversified asset base.”In total, five analysts have published buy ratings on the stock over the last three months- giving the stock a firm ‘Strong Buy’ consensus. Meanwhile the average analyst price target translates into 18% upside potential from current levels. Discover the Street's best-rated Trending Stocks over the last 7 days

  • Trinseo (TSE) Q2 2019 Earnings Call Transcript
    Motley Fool

    Trinseo (TSE) Q2 2019 Earnings Call Transcript

    TSE earnings call for the period ending June 30, 2019.

  • Local companies impacted by trade war-fueled stock market decline
    American City Business Journals

    Local companies impacted by trade war-fueled stock market decline

    Among the Philadelphia region’s largest 20 publicly traded companies, three in the chemical industry experienced the biggest dips in midday trading.

  • How Does Trinseo S.A. (NYSE:TSE) Stand Up To These Simple Dividend Safety Checks?
    Simply Wall St.

    How Does Trinseo S.A. (NYSE:TSE) Stand Up To These Simple Dividend Safety Checks?

    Dividend paying stocks like Trinseo S.A. (NYSE:TSE) tend to be popular with investors, and for good reason - some...

  • Business Wire

    Trinseo Releases 9th Annual Sustainability & Corporate Social Responsibility Report

    Trinseo (TSE), a global materials company and manufacturer of plastics, latex binders, and synthetic rubber, announced the release of its 2019 Sustainability and Corporate Social Responsibility (CSR) Report, which showcases how Trinseo is meeting or exceeding the highest standards of safety and environmental performance, while developing innovative solutions that benefit our world. This is the ninth report since the Company’s formation in 2010, and has been prepared in accordance with the Global Reporting Initiative (GRI) Standards Core Option.

  • Business Wire

    Trinseo Announces Release Date and Conference Call for its Second Quarter 2019 Financial Results

    Trinseo , a global materials solutions provider and manufacturer of plastics, latex binders and synthetic rubber, today announced that it will host a conference call to discuss its Second Quarter 2019 financial results on Friday, August 9 at 10 AM Eastern Time.

  • Read This Before You Buy Trinseo S.A. (NYSE:TSE) Because Of Its P/E Ratio
    Simply Wall St.

    Read This Before You Buy Trinseo S.A. (NYSE:TSE) Because Of Its P/E Ratio

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...

  • 3 Small Cap Stocks with Potential for Big Profit

    3 Small Cap Stocks with Potential for Big Profit

    In the past 12 months, small cap stocks did not perform well. All in all, the S&P SmallCap 600 lost 9% of its value (for the sake of comparison, the S&P 500 was able to climb by 10%). Microcaps have encountered greater difficulties and declined by 22%.True, as data shows, small stocks tend to be volatile, but they have their merits. They are relatively cheap to buy, and they have great potential for growth. The following three stocks shouldn’t be left unnoticed by investors as they provide excellent opportunities for future returns. Upwork – A New Concept of WorkMost people today follow a conventional work pattern. They wake up early in the morning, commute to work and return home in the evening. Upwork (NASDAQ:UPWK) strives to change that. It has built an online platform where freelancers working from home at their own free time offer their services to individuals or companies seeking different types of products from content and programming to financial or legal counseling. This new type of flexible work, referred to as the "gig economy", is still in its infancy in the United States with a market cap of a little more than $1.5 billion, but it is expected to rise exponentially in the future. Upwork is leading the way. Since is public debut in the autumn of 2018, Upwork stock lost 25% of its value. As alarming as this may sound, the stock has great potential. So far, Upwork has not been profitable, but there is room for optimism. In 2019 Q1, its revenue went higher by 16% year over year to $68.9 million. The analysts show the company’s stock ungrudging courtesy. On June 26, Brent Hill from Jefferies upgraded it from hold to buy with a price target of $23 from real price value of $15. Average analysts’ price target stands at $22.75 (43% upside ). This positive assessment is derived from Upwork’s growth potential in the freelance market. Analyst Ratings & Price Targets on Upwork Inc HEXO – Cannabis for Fun and HealingHEXO Corp (TSE:HEXO) is a Canadian company that produces and distributes cannabis for medical and recreational uses in the Canada. It deploys innovative cannabinoid isolation technology with its 1.8 million sq. ft of facilities located in Quebec, Ontario and Greece (indicating the company’s intentions to penetrate the Eurozone). HEXO’s production stood at 9,804 kilos in Q1 2019, nearly 100% higher quarter over quarter. Production forecast for fiscal 2020 issued by the company’s management revolves around 150,000 kilos, which is expected to increase annual revenues from approximately C$64 million at present to a whopping $400 million. Wall Street analysts are fully aware of HEXO’s potential. Russel Stanley from Beacon reiterated his buy recommendation for the company on June 13 setting a 12-month target price of $14 with a particularly big upside of 111 %. On June 12, the company released its third quarter fiscal 2019 (July 31 fiscal year end) financials showing gross and net revenue of $15.9 million and $13.0 million, respectively. Both were ahead of Stanley’s forecast of $12.3 million and $10.2 million, respectively.Having said that, one should bear in mind that high profit potential also entails risk. Owen Bennett from Jefferies has recently reiterated his assessment of the company’s stock to sell. He is concerned about HEXO’s earnings latest earnings release for the quarter ending January 31. The company reported a quarterly GAAP net loss of C$4.33 million. In comparison, last year the company had a GAAP net loss of C$1.97 million. This calls for a bit of caution before deciding to invest.Analyst Ratings & Price Targets on HEXO Corporation Inseego – Investing in a Breakthrough Technology5G technology is almost here and Inseego (NASDAQ:INSG) positions itself to be at its forefront by upgrading its already existing 4G cloud and networking solutions to the new generation. Despite currently being unprofitable, analysts expect the company to increase its annual revenues by 20% in the next 5 years. If that happens, its stock will most likely soar by around 80 % above its current price ($4.27 as of June 27).Michael Latimore from Northland Securities has recently reiterated his buy recommendation for the stock setting a price target of $6 (current stock value as of June 27 stands at $4.29) with an upside of 39.86%. In the last 3 months, Inseego insiders bought the company shares at a total worth $10.64 million and that is a good sign.Analyst Ratings & Price Targets on Inseego Corp What’s the Bottom Line?Some small cap stocks have great profit potential and it is crucial to be able to identify them. But as shown above, the greater the prospects for profit, the greater the risk. One of the major disadvantages of small stocks is their tendency to be volatile. Therefore, it is highly advised to closely monitor their performances over time, go over analysts’ assessments and, most of all, always stay alert to new developments that may change the overall picture. * * *

  • Business Wire

    Trinseo Announces Quarterly Dividend

    Trinseo , a global materials solutions provider and manufacturer of plastics, latex binders and synthetic rubber, today announced that its Board of Directors authorized a quarterly dividend of $0.40 per share.

  • Here’s What Hedge Funds Think About Trinseo S.A. (TSE)
    Insider Monkey

    Here’s What Hedge Funds Think About Trinseo S.A. (TSE)

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]

  • Markit

    See what the IHS Markit Score report has to say about Trinseo SA.

    Trinseo SA NYSE:TSEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for TSE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TSE. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding TSE are favorable, with net inflows of $1.12 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Basic Materials sector is rising. The rate of growth is weak relative to the trend shown over the past year, but is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Has Trinseo S.A. (NYSE:TSE) Been Employing Capital Shrewdly?
    Simply Wall St.

    Has Trinseo S.A. (NYSE:TSE) Been Employing Capital Shrewdly?

    Today we'll evaluate Trinseo S.A. (NYSE:TSE) to determine whether it could have potential as an investment idea. To be...

  • Near-Term Prospects Gloomy for Chemical Plastics Stocks

    Near-Term Prospects Gloomy for Chemical Plastics Stocks

    Near-Term Prospects Gloomy for Chemical Plastics Stocks

  • Top Analyst Weighs in on Canopy Growth and Cronos Group

    Top Analyst Weighs in on Canopy Growth and Cronos Group

    The global cannabis market is growing fast; it is currently valued at about $15 billion dollars and is expected to hit $150 billion by 2025 – a growth factor of 10, in just 6 years. Not many industries can boast that sort of return, and the potentialities of it are attracting established corporate interest in the cannabis companies. Alcohol and tobacco producers, especially, are making moves to enter the cannabis field, as a logical addition to current product lines. Dwelling in such an active market space, cannabis also draws attention from some of Wall Street’s best stock analysts.Martin Landry (Track Record & Ratings) is a five-star analyst with GMP FirstEnergy, and specializes in the consumer product and healthcare sectors. Legal cannabis, at the juncture of those two market segments, is squarely in his sights.In a series of recent reports and research notes, Landry turned his expertise on the emerging marijuana market. He takes note of cannabis’s recreational sector, and expresses his belief that the true future for this industry is in the medical field, supported by the linked factors of increasing numbers of patients, increasing numbers of prescribing doctors, and an expanding extract business giving both patients and doctors more options.In addition to his holistic view of the cannabis market, Landry also narrows his focus to particular cannabis companies. In recent weeks, he turned his gaze on two Canadian players, Canopy Growth and Cronos Group. Putting Canopy and Cronos together with TipRanks’ Stock Comparison tool, we can unpack their current market performance, and get a sense for where each is headed. It’s clear at a glance that Canopy is the larger company, with triple the market cap and share price – but Cronos has more than double the yearly equity gain. The analyst outlook on the two companies diverges even more sharply: Cronos has a ‘Moderate Sell’ rating, while Canopy has a ‘Moderate Buy’ consensus along with a 27% upside potential. A closer look at the data, and at Landry’s comments, will lay out the differences between them.View Canopy & Cronos in the TipRanks Stock Comparison ToolCanopy and Cronos trade in both Toronto and New York. Since both companies were first established in Canada, and remain headquartered there, we’ll use their Toronto Stock Exchange tickers and give prices in Canadian dollars. Canopy Growth Corporation (TSE:WEED – Research Report)Landry recently attended an invited tour of Canopy’s British Columbia greenhouse facilities, which he described as “running smoothly across all areas of production, trimming, and drying.” In his opinion, those facilities show potential for an annual production of 300 tons of cannabis and extract products.The BC greenhouses, of course, are only a small part of Canopy’s operations. The company controls over 5.5 million square feet of growing space, with over 4.4 million of that in licensed use. Canopy is currently producing over 10 tons per quarter, and is aiming for peak production, in two to three years, of 500 tons annually, or roughly twelve times current production. Landry is satisfied that Canopy can achieve this; back to his BC greenhouse tour, he said, “With a number of harvests already under the belt, the ramp up focus is on increasing yields and shortening cycle time. WEED expects it can achieve an equivalent of over four harvests per year.”Increased production potential is only one of Canopy’s advantages; the company has been at the center of two acquisition deals in recent months. In the first, announced last summer, Constellation Brands (STZ) – a giant in the international alcohol industry, and owner of Corona beer – increased its holding in Canopy from 10% to 38% with a US$4 billion investment. The move gives Constellation access to Canopy’s marijuana extracts to use in the production of cannabis infused beverages, while giving Canopy access to Constellation’s international network for beverage production and distribution.The Constellation investment gave Canopy a windfall of cash, which the cannabis company used in its turn to acquire Acreage Holdings (TSE:ACRG.U). Acreage, while headquartered in British Columbia, operates major cannabis production and distribution networks in the United States, with a presence in 20 states. The Canopy acquisition deal, worth US$3.4 billion, is unique in that it will not take effect until the US Federal government legalizes cannabis nationwide. To lock it in, Canopy has put down US$300 million.These two corporate maneuvers have put Canopy – and Constellation, for that matter – in a strong position to take advantage of new markets and expanding sales in the cannabis market.Landry gives WEED shares a target price of C$72, suggesting a 19% upside to the stock, and reflecting his optimism that the company can reach its production goals in the near-term. Canopy’s analyst consensus rating, a ‘Moderate Buy’ based on 7 buys and 4 holds from all of the analysts over the past three months, suggests that Landry is not alone in his upbeat outlook. The stock’s C$76 average price target gives it a 27% potential upside from the C$60 current share price.View TSE:WEED Price Target & Analyst Rating Detail Cronos Group, Inc. (TSE:CRON – Research Report)Cronos is the fourth-largest cannabis producer in North America, and a major competitor of Canopy. The size difference between the two companies, however, is obvious when comparing the recent quarterly production numbers. Cronos reported selling over 1.1 tons of cannabis products – only one-ninth the production of its larger rival.A larger problem for Cronos, however, lies in processing and packaging. The company has not yet fully developed these systems, and ended the March quarter with over 380 kilograms of finished product sitting in inventory. Landry points out this bottleneck in his review of the company, saying, “Cronos is testing investor patience with a slow production ramp-up and bottlenecks for processing and packaging. We believe these issues will be resolved before the summer which should result in a stronger back half for the company.”The bottlenecks, and the relatively low production, have impacted share price. CRON shares are down 36% since March. The fall in share price brings up the obvious question, should investors buy this stock on the dip? The decline, and the matter of purchase timing, also drew attention from Landry: “While Cronos’ shares have declined significantly from their 52-week high, we see limited near-term catalysts and investors should await a better entry point.”Like Canopy, Cronos has recently seen acquisition interest from a major “sin” company. In December, Altria Group (MO), one of the world’s largest tobacco companies, announced that it is acquiring a 45% stake in Cronos for C$2.4 billion ($1.8 billion in US currency). The move gives Cronos two immediate advantages: an infusion of cash, and more importantly, access to Altria’s know-how in processing and packaging. This acquisition deal underlies Landry’s belief that Cronos can resolve those bottlenecks by year’s end.For a longer-term advantage, Cronos will also have access to Altria’s sales and distribution network. As the maker of Marlboro cigarettes, Altria’s networks are a considerable asset, with an obvious marketing connection to the cannabis industry. Cronos CEO Mike Gorenstien noted all of these advantages when he said of the Altria deal, “We’re delighted to have officially closed our transaction with Altria and to kick off a relationship we expect to lead to significant growth and value creation. Altria’s investment and the services that Altria will provide to Cronos Group will enhance our financial resources and allow us to expand our product development and commercialization capabilities.”Analyst Landry puts a C$21 price target on CRON, suggesting a modest 4.6% upside to the stock. This goes along with his ‘Hold’ rating. Even so, his outlook on the stock is more upbeat than the analyst consensus of ‘Moderate Sell.’ That consensus is based on 1 buy, 6 holds, and 4 sells given in the past three months. Shares sell for C$20 in Toronto, to the C$20.60 average price target yields a 2.6% upside potential.View TSE:CRON Price Target & Analyst Rating Detail Enjoy Research Report on the Stocks in this Article:Canopy Growth Corporation (TSE:WEED) Research ReportCronos Group, Inc. (TSE:CRON) Research Report

  • 3 ‘Strong Buy’ Cannabis Stocks Set For Rapid Growth

    3 ‘Strong Buy’ Cannabis Stocks Set For Rapid Growth

    The cannabis market has the potential to be extremely lucrative for investors. For example Quebec-based cannabis grower Hexo Corp (HEXO) is now up 107% year-to-date. But you have to know which stocks to look out for- as not all cannabis stocks are primed for success. And one way to go about this is to find the stocks with the most bullish outlook according to the Street. Here we delve deeper into three such stocks, that all show a ‘Strong Buy’ consensus from top-performing analysts. These are the analysts who consistently outperform the market, so their advice is worth following. Let’s take a closer look now: GW Pharmaceuticals (NASDAQ:GWPH)There’s no denying that this cannabis biotech is on a roll. GWPH develops and commercializes plant based cannabinoid therapies. Its key drug Epidiolex is marketed for the treatment of seizures associated with LennoxGastaut syndrome and Dravet syndrome. And with a strong Epidiolex launch and uptake trends so far, management is already demonstrating impressive execution in a very competitive market.Most notably, GWPH has just reported Epidiolex revenues of $33.5M, more than double some estimates, thanks to uptake among new patients and the transition from expanded access and open-label extension programs (EAP/OLE) to commercial product. Even more importantly, the company also shared positive topline results from a Phase 3 study of Epidiolex in patients with seizures associated with tuberous sclerosis complex (TSC).Such strong earnings prompted Oppenheimer’s Esther Rajavelu to upgrade GWPH from ‘Hold’ to ‘Buy.’ Following this upgrade, GWPH has now received 10 back-to-back buy ratings from analysts covering the stock in the last three months. That’s with a $220 price target, indicating upside potential of over 23%. “GWPH is uniquely positioned as the only phytocannabinoid company with an FDA-approved, marketed therapeutic agent (Epidiolex), and a validated platform it can leverage broadly” Rajavelu told investors.She continues: “Our Outperform thesis is based on our view that the potential for Epidiolex use in multiple seizure types including those associated with tuberous sclerosis complex, as well as other pipeline opportunities, are not fully reflected in the stock at current levels.” Following the latest trial results, the analyst updated the the probability of approval of the sNDA (supplemental new drug application) for TSC to 87% from 41% previously, and expects the filing to be submitted in Q4. Interestingly, UK-based GWPH also boasts a ‘perfect’ Smart Score of 10/10. This new rating system compiles 8 different data sets- from analyst ratings to the latest insider activity- to rank stocks out of ten. Here GWPH scores highly not just with the analysts but also with both bloggers and hedge funds. That's alongside Very Positive news sentiment, and positive momentum with shares up 22% over the last year. See what other Top Analysts are saying about GWPH. Aphria Inc (NYSE:APHA)GWPH isn’t the only cannabis stock out there with strikingly positive Street sentiment. Canadian cannabis giant Aphria has also received only buy ratings from analysts in the last three months. That’s despite a horrific 2018 featuring a takeover attempt and short seller allegations of devious insider dealings. But with a board investigation complete and a new CEO at the helm (Irwin Simon) the tide is now turning. And so it’s worth taking a closer look at Aphria now while the stock is still trading at discounted levels. “We believe Aphria is on the cusp of a major production ramp along with significant economies of scale for production and SG&A costs. Given our increased CY2020e Adj. EBITDA estimate, we are raising our 12-month target price to $24.75 per share (from $22.75)” cheers Clarus analyst Noel Atkinson. From current levels this indicates huge upside potential of 136%.He blames limited capacity and production bottlenecks for the recent disappointing earnings results, but sees brighter days ahead. “If management can guide the pending production ramp effectively, we believe there is the potential for a very substantial re-rating of the stock price from current levels. We reiterate our Buy rating” the analyst concluded. Bear in mind, APHA shares have already exploded by 550% in the last three years. So what kind of growth can we expect? Well, management recently provided targets of $500MM of Canadian cannabis revenue (annual run-rate) by the end of CY2019 and $1 billion by the end of CY2020. That expansion now looks closer than ever due to the Health Canada licensing for the crucial Part IV/V expansion (80,000 kg/year) at Aphria One that was received right after quarter-end on March 4- which means Aphria One’s full capacity should reach consumers as early as this summer. Plus the new Aphria Diamond facility should come on line soon. “We continue to believe that Aphria has developed one of the most automated and highly sophisticated cultivation facilities in the world at Aphria One, and we expect Aphria Diamond (140,000 kg/year) to have similar capabilities once it is licensed” writes Atkinson. The analyst adds: “We understand Aphria Diamond is essentially completed and awaiting Health Canada inspection to begin cultivation.”From a Smart Score perspective however Aphria receives a more muted score of six. Even though the stock scores highly with both analysts and bloggers, and has a Very Bullish news sentiment for the past week, its sentiment from investors is Positive (vs Very Positive for GWPH) with both the technicals and fundamentals in the red. See what other Top Analysts are saying about APHA. Canopy Growth Corp (NYSE:CGC) (TSE:WEED)This piece would not be complete without our third stock, Canopy Growth Corp. In just one year shares in CGC, the world’s largest cannabis stock by market cap, have doubled. Now if you look at all the analyst ratings received by CGC over the last three months, the stock shows a cautiously optimistic Moderate Buy consensus. But if we include only those ratings published by best-performing analysts, the consensus shifts to Strong Buy. In fact, CGC has received five consecutive buy ratings from top-performing analysts in the last three months. And if we look at the Canadian ticker TSE:WEED, that’s with an average analyst price target of C$83, for upside potential of just over 30%. What’s more CGC’s most recent rating comes from Martin Landry of GMP FirstEnergy. This is one of the Top 20 analysts ranked by TipRanks out of over 5,190 analysts thanks to his savvy stock picking skills. He reiterated his buy rating on CGC with a C$72 price target- having upgraded the stock from Hold to Buy in April following the news that CGC has acquired the rights to snap up organic cannabis company Acreage Holdings. As far as the Street is concerned, this deal provides CGC with a straightforward “path for the U.S. cannabis market.” Landry himself writes “This transaction should boost Acreage’s ability to consolidate the U.S. market.” That means “when Canopy officially takes ownership of Acreage, it could be much larger than currently.”The analyst has now returned from a very insightful tour of the company’s activities in British Columbia (BC), including both the company’s Aldergrove and Delta facilities.“The BC greenhouses appear to be running smoothly across all areas of production, trimming and drying,” the analyst commented- silencing rumors of dead cannabis plants that have plagued CGC since a video back in 2018 purported to show total crop failure at Aldergrove.According to Landry, “The facilities are ramping up production with only 400k sq. ft. of greenhouse currently unlicensed, the application for which has been submitted. With a number of harvests already under the belt, the ramp up focus is on increasing yields and shortening cycle time. WEED expects it can achieve an equivalent of over four harvests per year. Canopy has trimming and drying capacity to handle the full production of the BC Tweed facilities.” He believes Canopy’s BC facilities could eventually produce 300 tonnes of cannabis annually, with a production cost of $0.50/ per gram.With the stock showing such strong momentum, CGC also sports a 10/10 from TipRanks’ Smart Score, despite Very Negative sentiment from investors. See what other Top Analysts are saying about CGC. Enjoy Research Reports on the Stocks in this Article:Aphria Inc (APHA) Research ReportCanopy Growth Corp (CGC) Research ReportGW Pharmaceuticals (GWPH) Research Report

  • Thomson Reuters StreetEvents

    Edited Transcript of TSE earnings conference call or presentation 3-May-19 2:00pm GMT

    Q1 2019 Trinseo SA Earnings Call

  • Business Wire

    Trinseo Named Ryan Leib, Bernard Skeete, and Lori Wilcox to New Roles on its Financial Leadership Team

    Trinseo (TSE), a global materials company and manufacturer of plastics, latex binders and synthetic rubber, announced the promotions of three key financial leaders to new roles within the organization, effective July 1, 2019. Ryan Leib has been named Vice President and Treasurer, succeeding Dave Stasse. Leib joined Trinseo in August of 2013 as Assistant Controller and was promoted to Corporate Controller in 2014.